A5091531260- HIV/AIDS drug development and treatment
- Pharmacological Effects and Toxicity Studies
- Antibiotics Pharmacokinetics and Efficacy
- HIV Research and Treatment
- Chronic Myeloid Leukemia Treatments
- Pharmacogenetics and Drug Metabolism
- Epilepsy research and treatment
- Pharmaceutical studies and practices
- Chronic Lymphocytic Leukemia Research
- Pregnancy and Medication Impact
- Drug Transport and Resistance Mechanisms
- Pneumocystis jirovecii pneumonia detection and treatment
- Pharmacovigilance and Adverse Drug Reactions
- Pharmaceutical Practices and Patient Outcomes
- Health, Medicine and Society
- Statistical Methods in Clinical Trials
- HIV-related health complications and treatments
- Neuropeptides and Animal Physiology
- Cancer Treatment and Pharmacology
- HIV/AIDS Research and Interventions
- Cannabis and Cannabinoid Research
- Anesthesia and Sedative Agents
- HER2/EGFR in Cancer Research
- Healthcare Systems and Practices
- Hemodynamic Monitoring and Therapy
University of Lausanne
2016-2025
University Hospital of Lausanne
2016-2025
University of Southern Denmark
2024
HES-SO University of Applied Sciences and Arts Western Switzerland
2024
Innovative Medicines for Tuberculosis Foundation
2022
Hôpital Orthopédique de la Suisse Romande
2004-2020
Immersion (United States)
2020
Médecins du Monde
2020
Civil Service
2017-2019
Institute of Social and Preventive Medicine
1991-2016
Voriconazole is the therapy of choice for aspergillosis and a new treatment option candidiasis. Liver disease, age, genetic polymorphism cytochrome CYP2C19, comedications influence voriconazole metabolism. Large variations in pharmacokinetics may be associated with decreased efficacy or toxicity.This study was conducted to assess utility measuring blood levels individualized dose adjustments.A total 181 measurements high-pressure liquid chromatography were performed during 2388 days 52...
Limited information exists on the clinical usefulness of drug level monitoring for efavirenz, a once-daily non-nucleoside reverse transcriptase inhibitor (NNRTI). The aim this study was to determine whether efavirenz plasma concentration could predict treatment failure and central nervous system (CNS) tolerability.Blood samples were obtained from 130 HIV-infected patients receiving in combination with other antiretroviral agents more than 3 months. Efavirenz concentrations measured by...
Abstract Purpose: Scarce information is available on the brain penetration of temozolomide (TMZ), although this novel methylating agent mainly used for treatment malignant tumors. The purpose was to assess TMZ pharmacokinetics in plasma and cerebrospinal fluid (CSF) along with its inter-individual variability, characterize covariates explore relationships between systemic or cerebral drug exposure clinical outcomes. Experimental Design: levels were measured by high-performance liquid...
Background Efavirenz (EFV) and nevirapine (NVP) are metabolized by cytochrome P450 2B6 (CYP2B6). Allele 516 G>T (Gln172His) is associated with diminished activity of this isoenzyme, may lead to differences in drug exposure. Methods We evaluated allele as a pharmacogenetic marker EFV NVP pharmacokinetics toxicity 167 participants receiving 59 recruited within the genetics project Swiss HIV Cohort Study. Drug concentrations were measured plasma peripheral blood mononuclear cells (PBMCs) from...
Objectives Glucagon-like peptide 1 receptor agonists (GLP1-RA) are indicated for the treatment of type 2 diabetes and more recently weight loss. The aim this study was to assess risks associated with GLP1-RA exposure during early pregnancy. Design This multicentre, observational prospective cohort compared pregnancy outcomes in women exposed either or obesity those two reference groups: (1) at least one non-GLP1-RA antidiabetic drug first trimester (2) a group overweight/obese without...
Objective The reverse transcriptase inhibitor efavirenz is currently used at a fixed dose of 600 mg/d. However, dosage individualization based on plasma concentration monitoring might be indicated. This study aimed to assess the pharmacokinetic profile and interpatient versus intrapatient variability in patients who are positive for human immunodeficiency virus, explore relationship between drug exposure, efficacy, central nervous system toxicity build up Bayesian approach adaptation....
Background. Recommended oral voriconazole (VRC) doses are lower than intravenous doses. Because plasma concentrations impact efficacy and safety of therapy, optimizing individual drug exposure may improve these outcomes. Methods. A population pharmacokinetic analysis (NONMEM) was performed on 505 concentration measurements involving 55 patients with invasive mycoses who received recommended VRC Results. 1-compartment model first-order absorption elimination best fitted the data. clearance...
The aims of this observational study were to assess the variability in imatinib pharmacokinetics and explore relationship between its disposition various biological covariates, especially plasma alpha1-acid glycoprotein concentrations.A population pharmacokinetic analysis was performed using NONMEM based on 321 samples from 59 patients with either chronic myeloid leukaemia or gastrointestinal stromal tumours. influence covariates oral clearance volume distribution examined. Furthermore, vivo...
ABSTRACT High-dose cefepime therapy is recommended for febrile neutropenia. Safety issues have been raised in a recent meta-analysis reporting an increased risk of mortality during therapy. Cefepime-related neurological toxicity has associated with overdosing due to severe renal dysfunction. This study aimed investigate the association between plasma concentrations and neutropenic patients. Cefepime trough (by high-performance liquid chromatography) were retrospectively analyzed 30 adult...
Biomarker-guided treatments are needed in psychiatry, and previous data suggest oxidative stress may be a target schizophrenia. A add-on trial with the antioxidant N-acetylcysteine (NAC) led to negative symptom reductions chronic patients. We aim study NAC's impact on symptoms neurocognition early psychosis (EP) explore whether glutathione (GSH)/redox markers could represent valid biomarkers guide treatment. In double-blind, randomized, placebo-controlled 63 EP patients, we assessed effect...
In order to improve the efficacy and safety of treatments, drug dosage needs be adjusted actual each patient in a truly personalized medicine approach. Key for widespread adjustment is availability point-of-care devices able measure plasma concentration simple, automated, cost-effective fashion. present work, we introduce test portable, palm-sized transmission-localized surface plasmon resonance (T-LSPR) setup, comprised off-the-shelf components coupled with DNA-based aptamers specific...
This contribution addresses the risk associated with exposure to statins during pregnancy.Multicentre observational prospective controlled study.European Network of Teratology Information Services.Pregnant women who contacted one 11 participating centres, seeking advice about pregnancy, or agents known be nonteratogenic.Pregnancies exposed first trimester were followed up prospectively, and their outcomes compared a matched control group.Rates major birth defects, live births, miscarriages,...
Abstract Complementary medicine (CM) is used by one third to half of cancer patients throughout the world. The objective this study was describe prevalence CM use and potential for interactions with treatments in an academic oncology centre. A cross-sectional conducted among undergoing current treatment. Among 132 included patients, 56% had since their diagnosis 45% were using during treatment at time survey. main green tea (35%), herbal homeopathy (27%), dietary supplements medicines (27%)....
The long-acting antiretroviral cabotegravir and rilpivirine combination has just received FDA, EMA Health Canada approval. This novel drug delivery approach is about to revolutionize the therapy of people living with HIV, decreasing 365 daily pill burden only six intramuscular injections per year. In addition, islatravir, a first-in-class nucleoside reverse transcriptase translocation inhibitor, intended be formulated as an implant dosing interval 1 year or more. At present, therapies...
To investigate pregnancy outcomes following maternal use of pregabalin.This multicenter, observational prospective cohort study compared in women exposed to pregabalin with those matched controls (not any medications known be teratogenic or antiepileptic drugs). Teratology Information Services systematically collected data between 2004 and 2013.Data were from 164 pregnancies 656 controls. A significantly higher major birth defect rate the group was observed after exclusion chromosomal...